Old Web
English
Sign In
Acemap
>
authorDetail
>
Sada Pillay
Sada Pillay
Eli Lilly and Company
Medicine
Glioma
Pharmacology
Pharmacokinetics
Transforming growth factor beta
5
Papers
58
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase 1, open-label, dose-escalation study of olaratumab as a single agent and in combination with doxorubicin, vincristine/irinotecan, or high-dose ifosfamide in pediatric patients with relapsed or refractory solid tumors.
2017
Journal of Clinical Oncology
Leo Mascarenhas
Datchen Fritz Tai
Michael W. Bishop
Steven G. DuBois
Theodore W. Laetsch
Donna E. Levy
Sada Pillay
Show All
Source
Cite
Save
Citations (0)
The oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: The first human dose study.
2017
Journal of Clinical Oncology
Analia Azaro
José Baselga
Juan Manuel Sepúlveda
Joan Seoane
Jordi Rodon Ahnert
Irene Brana
Ivelina Gueorguieva
Ann Cleverly
Michael Lahn
Sada Pillay
Luis Paz-Ares
Matthias Holdhoff
Jaishri Blakeley
Michael A. Carducci
Show All
Source
Cite
Save
Citations (10)
Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with gemcitabine in patients with advanced cancer.
2017
Journal of Clinical Oncology
Mark Kozloff
Rocío García Carbonero
Tamara Nadal
Ivelina Gueorguieva
Ann Cleverly
Durisala Desaiah
Michael Lahn
Sada Pillay
Al Blunt
Josep Tabernero
Teresa Macarulla
Show All
Source
Cite
Save
Citations (8)
Integrated data review of the first-in-human dose (FHD) study evaluating safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor, LY2157299 monohydrate (LY).
2013
Journal of Clinical Oncology
Jordi Rodon
Michael A. Carducci
Juan Manuel Sepúlveda
Analia Azaro
Emiliano Calvo
Joan Seoane
Irene Brana
Elisabet Sicart
Ivelina Gueorguieva
Ann Cleverly
Sada Pillay
Durisala Desaiah
Michael Lahn
Luis Paz-Ares
Matthias Holdhoff
Jaishri Blakeley
José Baselga
Show All
Source
Cite
Save
Citations (12)
First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma.
2011
Journal of Clinical Oncology
J. Rodon Ahnert
J. Baselga
Emiliano Calvo
Joan Seoane
Irene Brana
Elisabet Sicart
Ivelina Gueorguieva
Ann Cleverly
Michael Lahn
Sada Pillay
Matthias Holdhoff
Jaishri Blakeley
Michael A. Carducci
Show All
Source
Cite
Save
Citations (28)
1